What We're Reading: Page 346
Industry reads hand-picked by our editors
Mar 16, 2016
Mar 15, 2016
-
MIT Technology Review
T-Cell Pioneer Carl June Acknowledges Key Ingredient Wasn’t His
-
Reuters
Indian court grants temporary relief to Abbott, Glenmark in drug ban case
-
The Street
Celator Pharma Surprises With Blood Cancer Drug Survival Benefit
-
Waste Dive
Massachusetts becomes first state to mandate drug take-back program
Mar 14, 2016
-
Kansas City Star
U.S. hospitals try strategies to counter rising drug prices
-
Wall Street Journal
Bristol-Myers Bucks Trend Toward Precision Medicine
-
STAT
Is do-it-yourself CRISPR as scary as it sounds?
Mar 11, 2016
Mar 10, 2016
-
Stat
FDA deal with Amarin is unlikely to spark more off-label promotion
-
Washington Post
This drug is defying a rare form of leukemia — and it keeps getting pricier
-
FierceBiotech
Sarepta has a new date with an FDA AdCom for Duchenne drug eteplirsen
-
New York Times
Groups Scrutinize White House Plan to Cut Drug Costs in Medicare
Previous
